Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 3, 2007, Pages 311-317

  Wamalwa, Dalton C ^a   Farquhar, Carey ^b   Obimbo, Elizabeth M ^a   Selig, Sara ^c   Mbori Ngacha, Dorothy A ^a   Richardson, Barbra A ^b   Overbaugh, Julie ^d   Emery, Sandy ^d   Wariua, Grace ^a   Gichuhi, Christine ^a   Bosire, Rose ^e   John Stewart, Grace ^b  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

Antiretroviral; Children; HIV 1; Response

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NELFINAVIR; NEVIRAPINE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TUBERCULOSTATIC AGENT; VIRUS DNA; ZIDOVUDINE;

ANEMIA; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG RESPONSE; DRUG SUBSTITUTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; KENYA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; NUTRITIONAL SUPPORT; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; VIROLOGY; VIRUS LOAD; VOMITING; WORLD HEALTH ORGANIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIV-1; HUMANS; INFANT; KENYA; MALE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; WORLD HEALTH ORGANIZATION;

EID: 34347357578     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318042d613     Document Type: Article

References (26)

1. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;1345:1522-1528.
2. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS. 2004;18:1905-1913.
3. United Nations Program on HIV/AIDS. Report on the Global HIV/AIDS Epidemic, 2005, UNAIDS, Geneva, Switzerland.
4. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children in Resource-Limited Settings, Towards Universal Access: Recommendations for a Public Health Approach. World Health Organization, Geneva, Switzerland, February 2006.
5. Kenya NASCOP. Ministry of Health Guidelines to Antiretroviral Therapy in Kenya, 2003, Ministry of Health, Nairobi, Kenya.
6. Telgas J, Mayaux M, Blanche S. Antiretroviral therapy and mortality among children with perinatal HIV infection. JAMA. 2000;284:2871-2872.
7. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet. 2002;2:93-102.
8. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis. 1996;174:713-721.
9. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immuno-deficiency virus type 1 infection. N Engl J Med. 1997;336:1343-1349.
10. Hainaut M, Peltier CA, Gerard M, et al. Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1. Eur J Pediatr. 2000;159:778-782.
11. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1-infected children. AIDS. 2003;17:1639-1647.
12. Brogly S, Williams P, Seage GR, et al. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA. 2005;293:2213-2220.
13. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41:100-107.
14. Obimbo EM, Mbori-Ngacha DA, Ochieng JO, et al. Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected African children. Pediatr Infect Dis J. 2004;23:536-543.
15. United Nations Program on HIV/AIDS. Best Practice Collection: Paediatric HIV/AIDS Technical Update, 2001, UNAIDS, Geneva, Switzerland.
16. Emery S, Bodrug S, Richardson BA, et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol. 2000;38:2688-2695.
17. DeVange Panteleeff D, Emery S, Richardson BA, et al. Validation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples. J Clin Microbiol. 2002;40:3929-3937.
18. Centers for Disease Control and Prevention. Classification system for human immunodeficiency virus in children less than 13 years of age. MMWR Morb Mort Wkly Rep. 1994;43:1-10.
19. Kline MW, Matusa RF. Comprehensive human immunodeficiency virus care and treatment in Constanta, Romania. Pediatr Infect Dis J. 2004;23:695-700.
20. Resino S, Resino R, Maria Bellon J, et al. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis. 2006;43:243-252.
21. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS. 2003;17:541-545.
22. HIV Paediatric Prognostic Markers Collaborative Study. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-1 infected children: a meta-analysis of longitudinal data. Lancet. 2005;366:1868-1874.
23. Drain PKBJ, Overbaugh J, Wener MH, et al. Low serum albumin and the acute phase response predict low selenium in HIV-1 infected women. BMC Infect Dis. 2006;6:85.
24. Kupka RMG, Spiegelman D, Morris S, et al. Selenium status is associated with accelerated HIV disease progression among HIV-1 infected pregnant women in Tanzania. J Nutr. 2004;134:2556-2560.
25. Soh CH, Oleske JM, Brady MT, et al. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet. 2003;362:2045-2051.
26. Resino S, Resino R, Micheloud D, et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis. 2006;42:862-869.